Screener
Recursion Pharmaceuticals, Inc. RXRX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 3.5%— | 7.2%— | 5%— | —— | —— | |
| Operating margin | -991.7%+14.1pp | -881.3%+78.8pp | -867.9%-53.8pp | -1,656.2%-1,051pp | -1,005.8%-209pp | |
| Net margin | -945.9%+59.0pp | -842.9%+118pp | -863.4%-75.3pp | -1,637.8%-1,058pp | -1,004.9%-250pp | |
| Returns | ||||||
| Return on equity | -56.6%+29.8pp | -57.2%+28.9pp | -59.5%+2.4pp | -91.1%-12.6pp | -86.3%-15.2pp | |
| Return on invested capital | -116.4%+64.7pp | -118.2%+48.6pp | -124.6%+16.3pp | -209.8%+54.2pp | -181.1%+61.5pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0×-0.1× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 5×+1.5× | 5.5×+1.4× | 5.5×+1.7× | 4.6×+0.2× | 3.6×-2.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | 0.1×-0.1× | |
| Per Share | ||||||
| Book value per share | $1.72-22.0% | $1.94-16.5% | $2.53-33.0% | $2.34+26.2% | $2.20-8.7% | |
| Valuation | ||||||
| Market capitalization | $1.7B-28.6% | $1.62B-23.7% | $2.13B-19.4% | $2.13B+14.4% | $2.12B+16.8% | |
| Price / sales | 31×-5.9× | 24.4×-11.1× | 28.5×-16.4× | 48.8×+20.2× | 32.8×-3.7× | |
| Price / book | 1.9×-0.7× | 1.6×-0.7× | 1.9×-0.7× | 2×-1.5× | 2.3×-0.8× |
FAQ
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Recursion Pharmaceuticals, Inc. (RXRX) runs a 3.5% gross margin and a -991.7% operating margin, with a -945.9% net margin.
- Where do Recursion Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Recursion Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
